Interviews

Sarfaraz Niazi, PhD, an adjunct professor of biopharmaceutical Sciences at the College of Pharmacy at the University of Illinois at Chicago, discusses how the COVID-19 (coronavirus) pandemic is affecting drug shortages, challenging the FDA, and creating an greater opportunity for biosimilars down the road.

Surya Singh, MD, discussed dynamics that affect biosimilar uptake on the medical benefits side and how that differs from the pharmacy benefits side at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.

Soumi Saha, PharmD, JD, senior director of advocacy at Premier, Inc, discusses drug shortages caused by coronavirus disease (COVID-19) and policy recommendations that could fix the problem.

Christine Simmon discussed the Purple Book and how it will affect biosimilar makers and illuminate patent hurdles at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.

Matt Harman talks about what employers can do to help promote biosimilar adoption in the United States, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

Matt Harman talks about employer interest in biosimilar promotion and how the FDA's new biologics pathway change will affect interest levels, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

Wayne Winegarden, PhD, talked about the issues and benefits of the FDA's switch to a biologics regulatory pathway for certain products, especially insulin, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

Sheila Frame, the vice president of marketing, market access, and patient services at Sandoz, discusses US biosimilar policies in development and the impact they will have on the market at the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California.

Wayne Winegarden, PhD discusses the potential savings inherent in biosimilars at the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California.

Gillian Woollett, MA, DPhil, senior vice president, Avalere Health, explains the importance of consistency in applying critical product quality attributes.

Using biosimilars to reduce costs of cancer care is necessary, says Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center.

Gillian Woollett, MA, DPhil, senior vice president, Avalere Health, explains potential consequences if the United States were to do away with biosimilars.

Lindsey Roeker, MD, clinical fellow at Memorial Sloan Kettering Cancer Center, discusses adding rituximab to venetoclax to allow for a 2-year fixed-duration treatment schedule for patients with chronic lymphocytic leukemia (CLL).

Brian Lehman, MBA, MHA, RPh, director, Medical Account Management and Strategic Alliances, Sandoz, discusses the March 2020 transition of insulin to the biologics pathway.

Gillian Woollett, MA, DPhil, senior vice president, Avalere Health, discusses how “confirmation of sufficient likeness" should replace “totality of evidence” in biosimilar development.

Cate Lockhart, PharmD, PhD, discusses the research reports the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) plans on releasing in 2020.

Tesh Khullar, senior vice president and advisor, Flatiron Health, discusses the impact biosimilars could make in community oncology.

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses what she will be watching closely in the biosimilars space in early 2020.

Tesh Khullar, senior vice president and advisor, Flatiron Health, discusses challenges with reimbursement for biosimilars in community oncology practices.

Elaine Husni, MD, MPH, vice chair and director of the Arthritis and Musculoskeletal Center in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic, discusses whether biosimilars are generating cost savings for patients with inflammatory diseases.

Rhett Wilkerson, associate director of patient financial services, Florida Cancer Specialists, discusses how utilization management strategies impact patient access to biologics.

Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses how patients are responding to using biosimilars.

Tesh Khullar, senior vice president and advisor, Flatiron Health, discusses biosimilar education for patients and providers.

Tracy L. Bahl, president and chief executive officer of OneOncology, discusses the education his organization has provided to physicians on biosimilars.

Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses the role of body weight in treatment outcomes for inflammatory bowel disease (IBD).

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses how anticancer biosimilars have played a role in oncology in 2019.

Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses what oncologists have learned from experience with supportive care that can be applied to adopting anticancer biosimilars.

Erich Mounce, chief operating officer, OneOncology, discusses the role that biosimilars will have in practices meeting Oncology Care Model (OCM) goals.

Brian Lehman, MBA, MHA, RPh, director, Medical Account Management and Strategic Alliances, Sandoz, discusses positive developments for biosimilars over the past year.

Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses how biosimilars have impacted innovation in oncology.